Active ingredientTrametinibCat. No. P-T174-001CAS 871700-17-3Family · Pharmaceutical analytical standards
Trametinib
An inhibitor of the MEK1 and MEK2 kinases, approved in the United States in May 2013 for melanoma with a BRAF V600 mutation; today it is often combined with dabrafenib. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?Since 2014 it has been paired with dabrafenib: the two drugs block two consecutive links of the same signalling chain, BRAF and MEK, which drives melanoma cells to multiply.
Go to the active ingredient →Active ingredientTrametinibCat. No. P-T174-001CAS 871700-17-3
MetaboliteDesacetyl Trametinib O-glucuronideCat. No. P-T174-002CAS 1620017-28-8
Isotopically labelledTrametinib-13C-d3Cat. No. P-T174-003CAS 2712126-59-3
Isotopically labelledTrametinib-13C6Cat. No. P-T174-004
Isotopically labelledTrametinib-d4Cat. No. P-T174-005
Isotopically labelledTrametinib-d6Cat. No. P-T174-006
NitrosamineTrametinib N-Nitroso ImpurityCat. No. P-T174-007
ImpurityTrametinib Impurity 1Cat. No. P-T174-009CAS 871700-28-6
ImpurityDeiodo TrametinibCat. No. P-T174-010CAS 871700-65-1
Active ingredientTrametinib Dimethyl SulfoxideCat. No. P-T174-013CAS 1187431-43-1
ImpurityTrametinib Hydroxy ImpurityCat. No. P-T174-014CAS 871700-24-2
ImpurityTrametinib Impurity 2Cat. No. P-T174-015CAS 1383430-03-2
ImpurityTrametinib Impurity 3Cat. No. P-T174-016CAS 1620017-29-9
ImpurityTrametinib Impurity 4Cat. No. P-T174-017CAS 1383430-04-3
ImpurityTrametinib Impurity 5Cat. No. P-T174-018CAS 3018911-27-5
ImpurityTrametinib Impurity 6Cat. No. P-T174-019CAS 871700-25-3
ImpurityTrametinib Impurity 7Cat. No. P-T174-020
ImpurityTrametinib, desacetylCat. No. P-T174-021CAS 871701-87-0No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.